3 completed, 3 withdrawn, 2 recruiting, 2 unknown. 10 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 10 | Completed 3, Withdrawn 3, Recruiting 2, Unknown 2 |
Follow Cbd: new trials by email Literature Review of Cbd trials Research Report on Cbd
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors Cannabidiol, Delta-8-Tetrahydrocannabinol, Placebo Administration - Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy | Early Phase 1 | Withdrawn | City of Hope Medical Center | 2024-07-06 | 2024-08-09 | |
| Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel Cannabidiol in the form of hemp, Clopidogrel - Interaction | Early Phase 1 | Recruiting | Washington State University | 24 | 2024-06-20 | 2026-06-04 |
| Cannabidiol Effects on Fear Extinction in Social Phobia Fear extinction, Cannabidiol Cap/Tab, Placebo - Social Anxiety Disorder | Early Phase 1 | Unknown | Hartford Hospital | 20 | 2024-04-30 | 2024-04-19 |
| Cannabidiol Oil Extract for Prevention of Postoperative Nausea and Vomiting Cannabidiol Oil, Placebo - Postoperative Nausea and Vomiting | Early Phase 1 | Unknown | The University of The West Indies | 120 | 2023-09-21 | 2023-11-18 |
| Cannabidiol Effects on Cardiovascular System and Exercise Responses Placebo, Cannabidiol - Healthy | Early Phase 1 | Withdrawn | Castleton University | 2023-07-01 | 2024-03-27 | |
| Topical Cannabidiol Cream and Post-exercise Recovery Cannabidiol Oil, Resistance Exercise - Muscle Damage | Early Phase 1 | Withdrawn | University of New Mexico | 2023-05-15 | 2023-05-17 | |
| Cannabidiol in Opioid Use Disorder and Chronic Pain 400 mg Cannabidiol, 800 mg Cannabidiol, 1200 mg Cannabidiol - Chronic Pain, Opioid Use Disorder | Early Phase 1 | Completed | Yale University | 23 | 2021-12-08 | 2026-10-13 |
| Cannabidiol in Opioid Use Disorder and Chronic Pain With Buprenorphine 400 mg Cannabidiol, 800 mg Cannabidiol, 1200 mg Cannabidiol - Chronic Pain, Opioid Use Disorder | Early Phase 1 | Recruiting | Yale University | 34 | 2021-12-08 | 2026-10-21 |
| Cannabidiol and Autonomic Function at Rest cannabidiol, Placebo - Healthy | Early Phase 1 | Completed | Castleton University | 18 | 2021-08-30 | 2023-05-15 |
| Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC) Delta-9-Tetrahydrocannabinol, Cannabidiol, Placebos - Chronic Pain, Widespread | Early Phase 1 | Completed | University of Utah | 53 | 2018-02-01 | 2025-04-13 |
Chronic Pain (3) · Opioid-Related Disorders (2) · Pain (2) · Breast Neoplasms (1) · Colonic Neoplasms (1) · Motor Activity (1) · Patient Satisfaction (1) · Phobia, Social (1) · Postoperative Nausea and Vomiting (1)
Castleton University (2) · Yale University (2) · City of Hope Medical Center (1) · Hartford Hospital (1) · The University of The West Indies (1) · University of New Mexico (1) · University of Utah (1) · Washington State University (1)
United States (9) · Jamaica (1)
Joao De Aquino, M.D. (2) · David Tolin, Ph.D. (1) · Deborah Yurgelun-Todd, Ph.D. (1) · Fabiano Amorim, PhD (1) · Ingrid Tennant, DM, PhD (1) · Richard T Lee (1)
K23DA052682 (1), P30CA033572 (1), R21CA260447 (1), U54AT008909 (1)